Latest news with #RecombinantHumanAlbumin
Business Standard
23-05-2025
- Business
- Business Standard
Shilpa Medicare zooms as arm partners with Orion Corporation
Shilpa Medicare jumped 7.88% to Rs 792.90 after its wholly owned subsidiary, Shilpa Biocare, entered into a strategic partnership with Orion Corporation to commercialise Recombinant Human Albumin in Europe. Under this strategic agreement, Orion Corporation will serve as the exclusive partner for the distribution, marketing, and sales of Shilpas Recombinant Human Albumin in Europe. As part of the deal, Shilpa is entitled to receive development and regulatory milestone payments from Orion. Shilpa has been investing in the development of this novel product for approximately eight years, including the establishment of a large-scale fermentation facility designed to manufacture recombinant human albumin. This facility aims to meet the global demand for this life-saving drug. The collaboration with Orion marks a major milestone in Shilpas expansion into the global biosimilar and biopharmaceutical markets, leveraging Orions strong regional presence, regulatory expertise, and established commercial infrastructure. The firm stated that Orion Corporation is not a related party to the company, Shilpa Biocare (SBPL), or any of the promoter/promoter group/group companies. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications and as a critical component in vaccine and biologics manufacturing. Shilpa Medicares recombinant human albumin is developed using a robust non-human expression system, ensuring high safety, scalability, and virus-free production, effectively addressing key limitations associated with human-derived albumin. This partnership reinforces both companies commitment to advancing biotechnology-driven therapies and improving patient access to safer, sustainable, and next-generation biologics. Madhav Bhutada, Managing Director, Shilpa Biocare, said, partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental & manufacturing capabilities to bring recombinant human albumin to market. This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets. Satu Ahomi, EVP Generics and Consumer Health, Orion Corporation, said, We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product. Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe. Shilpa Medicare is a manufacturer of API, formulation, and development services. Shilpa Medicare (SML) started its operations as an API manufacturer way back in 1987 at Raichur, Karnataka, India. The company had reported a consolidated net profit of Rs 31.78 crore in Q3 FY25, which is significantly higher as compared with the PAT of Rs 4.58 crore posted in Q3 FY24. Revenue from operations for the third quarter was at Rs 319.32 crore, up 11.35% year on year.
Yahoo
23-05-2025
- Business
- Yahoo
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited ('Shilpa'), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa's Recombinant Human Albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin. The product is currently under development by Shilpa. Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa's Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. 'We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,' said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. 'Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.' 'Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market,' said Madhav Bhutada, Managing Director, Shilpa Biocare. 'This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.' Orion Corporation Contact person:Satu Ahomäki, EVP, Generics and Consumer Health, Orion Corporation tel. +358 10 426 7616 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp:// Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki.
Yahoo
23-05-2025
- Business
- Yahoo
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited ('Shilpa'), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa's Recombinant Human Albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin. The product is currently under development by Shilpa. Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa's Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments. 'We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,' said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. 'Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.' 'Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market,' said Madhav Bhutada, Managing Director, Shilpa Biocare. 'This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.' Orion Corporation Contact person:Satu Ahomäki, EVP, Generics and Consumer Health, Orion Corporation tel. +358 10 426 7616 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp:// Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
23-05-2025
- Business
- Business Upturn
Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe
By Aman Shukla Published on May 23, 2025, 15:05 IST Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic agreement with Orion Corporation, a pharmaceutical company based in Finland. The agreement grants Orion exclusive rights to distribute, market, and sell Shilpa's Recombinant Human Albumin in the European market. The product, currently under development, is a biosimilar version of human albumin produced using a non-human expression system. This production approach aims to offer an alternative to plasma-derived albumin by eliminating risks related to human pathogens and improving scalability. As part of the agreement, Shilpa Biocare is eligible to receive development and regulatory milestone payments from Orion. Shilpa has been investing in the development of Recombinant Human Albumin for approximately eight years and has established a large-scale fermentation facility to support its production. Recombinant Human Albumin is used in a variety of therapeutic applications and plays a critical role in the manufacturing of vaccines and other biologics. The collaboration is expected to leverage Orion's experience in the European pharmaceutical market, including its regulatory and distribution capabilities. The partnership reflects ongoing industry efforts to enhance the availability of biologics and biosimilars that meet safety and quality standards. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
